rs12086634 — HSD11B1 Intron 3 variant

HSD11B1 Intron 3 — The Tissue Cortisol Switch

Your adrenal glands release cortisone, an inactive form of cortisol, into the bloodstream. Inside tissues — particularly liver, adipose tissue, and brain — the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1, encoded by HSD11B1) converts cortisone back into active cortisol¹¹ cortisol
the primary stress glucocorticoid, with wide effects on glucose, fat, and immune function. This local amplification means that intracellular cortisol concentrations in fat and liver can substantially exceed plasma levels — a separate, tissue-controlled glucocorticoid environment. The rs12086634 variant sits in an enhancer element in intron 3²² enhancer element in intron 3
a non-coding regulatory region that boosts transcription of the nearby gene of HSD11B1 and modulates how much enzyme is produced. Because the G allele reduces transcription in vitro, carriers produce less 11beta-HSD1 and regenerate less cortisol locally, while the common T allele (especially TT homozygotes combined with the rs846910 A allele) is linked to higher enzyme expression and activity.

The Mechanism

The intron 3 enhancer region of HSD11B1 responds to tissue-specific transcription factors. In vitro reporter assays show that the G allele reduces transcriptional activity³³ reduces transcriptional activity
Draper et al. J Clin Endocrinol Metab 2006 compared to the common T allele. Less enzyme means less cortisone-to-cortisol conversion in adipose tissue and liver. The downstream consequences run in two directions: (1) lower local glucocorticoid activity may reduce visceral fat deposition and insulin resistance risk — hence the G allele's protective signal in some populations; (2) the corresponding higher cortisol clearance (more cortisol excreted as cortisone) triggers the HPA axis to compensate, increasing ACTH-driven adrenal output and paradoxically raising adrenal androgen production in susceptible individuals.

The enzyme relies on NADPH provided by hexose-6-phosphate dehydrogenase (H6PD)⁴⁴ NADPH provided by hexose-6-phosphate dehydrogenase (H6PD)
H6PD acts as the luminal NADPH generator; mutations in H6PD cause cortisone reductase deficiency in the endoplasmic reticulum lumen. Reduced HSD11B1 expression shifts the enzyme's net directionality away from cortisol regeneration toward cortisone formation.

The Evidence

A study of 102 Caucasian PCOS patients vs 98 controls⁵⁵ 102 Caucasian PCOS patients vs 98 controls
Draper et al. J Clin Endocrinol Metab 2006 found the G allele associated with PCOS status (P = 0.041), driven entirely by lean patients (P = 0.025). G allele carriers had lower morning plasma cortisol and higher ACTH-stimulated cortisol response⁶⁶ lower morning plasma cortisol and higher ACTH-stimulated cortisol response
suggesting enhanced cortisol clearance with compensatory HPA activation, elevated DHEA-S, and — notably — lower LDL cholesterol, consistent with reduced glucocorticoid activity in the liver. These findings suggest the G allele may confer metabolic protection while simultaneously predisposing lean women to adrenal hyperandrogenism.

A larger study of 600 women with and without PCOS⁷⁷ 600 women with and without PCOS
Gambineri et al. Eur J Endocrinol 2011 found that the TT genotype at rs12086634 combined with the rs846910 A allele (GA/TT haplotype) was associated with metabolic syndrome at OR 2.77 (95% CI 1.16–6.67), P = 0.023⁸⁸ OR 2.77 (95% CI 1.16–6.67), P = 0.023, regardless of PCOS diagnosis. Women with this haplotype had higher HSD11B1 mRNA in adipose tissue and a significantly elevated cortisol regeneration rate (16.1 ± 0.7 vs 12.1 ± 1.1 nmol/min, P = 0.044). This positions the T allele (not G) as the risk allele for metabolic syndrome in the context of the combined haplotype.

In 616 South Indian subjects⁹⁹ 616 South Indian subjects
Velmurugan et al. Endocr Connect 2017, the TG genotype (one G copy) contributed to increased risk of both type 2 diabetes (OR 1.91; 95% CI 1.33–2.76, P = 0.0005) and metabolic syndrome (OR 2.37; 95% CI 1.39–4.05, P = 0.0015), and was associated with elevated systolic blood pressure compared to TT controls. This contrasts with some European studies and underscores the population-dependent complexity of these associations.

A systematic review¹⁰¹⁰ systematic review
Torchen et al. Int J Diabetes Dev Ctries 2015 concluded that HSD11B1 variants play only a small role in most populations, with stronger associations in Indian and Pima Indian cohorts, and largely null findings in East Asian and French-Canadian populations.

Separately, HSD11B1 polymorphisms in intron 5¹¹¹¹ HSD11B1 polymorphisms in intron 5
Stavrou et al. Osteoporos Int 2009 were significantly associated with femoral neck bone mineral density (P = 0.00005) and vertebral fracture risk in 1,329 postmenopausal women, consistent with the known role of local glucocorticoid excess in suppressing osteoblast activity and promoting adipogenic differentiation of bone marrow progenitor cells.

Practical Implications

For people carrying the G allele (GT or GG), the likely effect is modestly reduced 11beta-HSD1 activity — meaning less local cortisol regeneration in fat and liver. This may offer metabolic protection (lower visceral fat accumulation tendency) but at the cost of higher HPA axis activity. For TT homozygotes, particularly those who also carry the rs846910 A allele, the evidence points toward elevated tissue cortisol regeneration, which manifests as higher metabolic syndrome risk, elevated fasting glucose, and in women, a tendency toward visceral fat accumulation.

Monitoring fasting glucose and waist circumference is particularly relevant for TT homozygotes. Compounds that reduce 11beta-HSD1 activity — including liquorice-derived carbenoxolone¹²¹² liquorice-derived carbenoxolone
a non-selective 11beta-HSD inhibitor studied in clinical trials, and dietary patterns that lower cortisol burden — have been explored as strategies but are not yet clinically actionable for this specific variant. Selective 11beta-HSD1 inhibitors remain in pharmaceutical development.

For bone health, the broader HSD11B1 data on fracture risk and BMD suggests that individuals with high local glucocorticoid activity (likely TT carriers with elevated enzyme expression) should prioritize bone density monitoring as they age.

Interactions

The functionally important interaction is with rs846910 in the HSD11B1 promoter region. The Gambineri 2011 study demonstrates that the combined GA (rs846910) + TT (rs12086634) haplotype is the high-activity combination: together they elevate HSD11B1 mRNA expression and cortisol regeneration rate in adipose tissue, with OR 2.77 for metabolic syndrome. Single-SNP analyses of either variant alone show weaker effects. This is a classic gene-gene interaction within the same gene — the two regulatory variants appear to act additively on transcriptional output.

Compound interaction proposal: Individuals carrying rs846910 GA genotype AND rs12086634 TT genotype both have an approximately 2.8-fold elevated metabolic syndrome risk and higher adipose cortisol regeneration. The combined recommendation for this haplotype: monitor fasting glucose, insulin, and waist circumference annually, and consider time-restricted eating patterns that minimize cortisol-mediated postprandial insulin surges. Both individual variant recommendations are subsumed by this combined finding.